STOCK TITAN

Tempus to Report Third Quarter 2026 Financial Results on November 2

Tempus AI (TEM) will report its third-quarter 2026 financial results before U.S. markets open on November 2, 2026.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
earnings date
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the third quarter ended September 30, 2026, before U.S. markets open on Monday, November 2, 2026.

The company will host a conference call and live audio webcast at 8:45 a.m ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers.

The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website or directly via the webcast link. Alternatively, the call can be accessed via the following:

Conference ID: 579 261 752
North America (Toll-Free): 1(833) 461-5787
International (Toll): +1 (585) 542-9983

For those unable to listen to the live broadcast, a recording will be available on the website following the call.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit www.tempus.com.

Investors
Elizabeth Krutoholow
Kendra Webster
investorrelations@tempus.com

Media
Kelli Manalli
media@tempus.com

Source: Tempus AI, Inc.

Keep reading